Achondrogenesis is a severe congential growth hormone deficiency that affects cartilage and bone development. This rare genetic disease is characterized by narrow chest, rounded abdomen, and extremely short limbs. There are majorly three types of achondrogenesis, type 1A, type 1B and type 2. Out of these three, type 1B is most severe and caused by mutations in the SLC26A2 gene. Achondrogenesis type 1B (ACG1B) is also known as Parenti-Fraccaro type. Achondrogenesis exhibits various symptoms such as, abdominal distention, flat face, anteverted nares, frontal bossing, lethal skeletal dysplasia, hydropsfetalis, abnormal enchondral ossification, and many others. According to the U.S National Library of Medicine, the incidence of 1A and 1B, whereas achondrogenesis type 2 occur in 1 in 40,000 to 60,000 newborns. The condition of achondrogenesis type 2 is mostly found in combination with hypochondrogenesis.

Appropriate treatment for the condition is unknown but to deal with the symptoms associated with achondrogenesis, palliative care is suggested by physicians. Genetic Counseling is also recommended to the people who have genetic disorders in their family history. Diagnosis or testing of achondrogenesis is based on histopathologic, clinical, and radiologic features. As per an article published in GeneReviews book, it is found that SLC26A2 is the only mutated gene known to cause ACG1B. Out of all the testing methods, molecular genetic testing is the most commonly used diagnosis for Achondrogenesis Type 1B. Molecular genetic testing method includes targeted mutation analysis, sequence analysis, and deletion/duplication analysis.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4668

It is estimated that achondrogenesis market is expected to grow at a CAGR 3.9% during the forecast period of 2017-2023.

Regional Analysis

The Americas dominate the achondrogenesis market owing to the rise in awareness among people, and high healthcare expenditure. According to the Centers for Disease Control and Prevention, in 2015, the total health expenditure in the United States was reported as USD 3.2 trillion and hospital care accounted for a share of 32.3%.

Europe holds the second position in achondrogenesis market. It is expected that the support provided by government bodies for research & development and improvement in reimbursement policies in healthcare will drive the market in Europe region.

Asia Pacific is the fastest growing achondrogenesis market owing to the huge patient pool and developing healthcare technology.

Segmentation

The achondrogenesis market is segmented on the basis of type, diagnosis, and end-users.

On the basis of type, market is segmented into surgery achondrogenesis type IA (Houston-Harris type), achondrogenesis type IA (Houston-Harris type), and achondrogenesis type II (Langer-Saldino type).

On the basis of diagnosis, market is classified into physical examination, molecular genetic testing, and biochemical testing. Physical examination is further classified into X-ray, ultrasound, and others. Molecular genetic testing is also further segmented into Chorionic Villus Sampling (CVS), aminocentesis, and others.

On the basis of end-users, market is segmented into hospital & clinics, diagnostic centers, research & academic institutes, and others.

Key Players

Some of key the players in the achondrogenesis market are Cook, Thermo Fisher Scientific, CooperSurgical Inc., Illumina, Inc., Siemens AG, FUJIFILM Holdings Corporation, Koninklijke, Philips N.V., Stryker, Toshiba Corporation, Invivoscribe, Abbott Molecular Inc., INVITROGEN CORPORATION, Roche Molecular Systems, Inc., and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/achondrogenesis-market-4668